Rezolute (RZLT) Cost of Revenue (2013 - 2021)
Rezolute recorded quarterly Cost of Revenue of $204000.0 in Q2 2021, down 19.37% quarter-over-quarter from $253000.0 in Q1 2021, and up 29.94% year-over-year from $157000.0 in Q2 2020.
Rezolute's Cost of Revenue history runs 9 years deep, the most recent figure standing at $204000.0 for Q2 2021.
- In Q2 2021, Cost of Revenue rose 29.94% year-over-year to $204000.0; the TTM figure through Jun 2021 stood at $765000.0 (down 13.27% YoY), while the FY2021 annual figure was $765000.0, down 13.27% from the prior year.
- Cost of Revenue came in at $204000.0 for Q2 2021 at Rezolute, down from $253000.0 in the prior quarter.
- In the past five years, Cost of Revenue ranged from a high of $678000.0 in Q2 2019 to a low of $9000.0 in Q1 2019.
- A 5-year average of $268488.6 and a median of $227602.0 in 2017 frame the typical range for Cost of Revenue.
- Across the five-year window, Cost of Revenue sank 95.89% in 2019 and surged 3055.56% in 2020, its largest moves.
- Rezolute's Cost of Revenue stood at $227602.0 in 2017, then jumped by 107.38% to $472000.0 in 2018, then sank by 46.19% to $254000.0 in 2019, then slumped by 47.24% to $134000.0 in 2020, then jumped by 52.24% to $204000.0 in 2021.
- According to Business Quant data, Cost of Revenue over the past three periods registered $204000.0, $253000.0, and $134000.0 for Q2 2021, Q1 2021, and Q4 2020 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 64.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 392.80 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 296.00 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 207.52 Mn |
| 10 | Rezolute | 374.41 Mn | 374.41 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2021 | 204,000.00 |
| Jun 30, 2021 | 204,000.00 |
| Mar 31, 2021 | 253,000.00 |
| Mar 31, 2021 | 253,000.00 |
| Dec 31, 2020 | 134,000.00 |
| Dec 31, 2020 | 134,000.00 |
| Sep 30, 2020 | 174,000.00 |
| Sep 30, 2020 | 174,000.00 |
| Jun 30, 2020 | 157,000.00 |
| Jun 30, 2020 | 157,000.00 |
| Mar 31, 2020 | 284,000.00 |
| Mar 31, 2020 | 284,000.00 |
| Dec 31, 2019 | 254,000.00 |
| Dec 31, 2019 | 254,000.00 |
| Sep 30, 2019 | 187,000.00 |
| Sep 30, 2019 | 187,000.00 |
| Jun 30, 2019 | 678,000.00 |
| Jun 30, 2019 | 678,000.00 |
| Mar 31, 2019 | 9,000.00 |
| Mar 31, 2019 | 9,000.00 |
| Dec 31, 2018 | 472,000.00 |
| Dec 31, 2018 | 472,000.00 |
| Sep 30, 2018 | 73,000.00 |
| Sep 30, 2018 | 73,000.00 |
| Jun 30, 2018 | 289,117.00 |
| Jun 30, 2018 | 289,117.00 |
| Mar 31, 2018 | 219,192.00 |
| Mar 31, 2018 | 219,192.00 |
| Dec 31, 2017 | 227,602.00 |
| Dec 31, 2017 | 227,602.00 |
| Sep 30, 2017 | 426,089.00 |
| Sep 30, 2017 | 426,089.00 |
| Jun 30, 2017 | 523,306.00 |
| Jun 30, 2017 | 523,306.00 |
| Sep 30, 2016 | 511,707.00 |
| Sep 30, 2016 | 511,707.00 |
| Jun 30, 2016 | 577,598.00 |
| Jun 30, 2016 | 577,598.00 |
| Mar 31, 2016 | 461,599.00 |
| Mar 31, 2016 | 461,599.00 |
| Dec 31, 2015 | 755,464.00 |
| Dec 31, 2015 | 755,464.00 |
| Sep 30, 2015 | 620,143.00 |
| Sep 30, 2015 | 620,143.00 |
| Jun 30, 2015 | 484,574.00 |
| Jun 30, 2015 | 484,574.00 |
| Mar 31, 2015 | 296,385.00 |
| Mar 31, 2015 | 296,385.00 |
| Dec 31, 2014 | 462,365.00 |
| Dec 31, 2014 | 462,365.00 |
| Sep 30, 2014 | 112,558.00 |
| Sep 30, 2014 | 112,558.00 |
| Jun 30, 2014 | -223,302.00 |
| Jun 30, 2014 | -223,302.00 |
| Mar 31, 2014 | 2,246.00 |
| Mar 31, 2014 | 2,246.00 |
| Dec 31, 2013 | 548,556.00 |
| Dec 31, 2013 | 548,556.00 |
| Sep 30, 2013 | 42,735.00 |
| Sep 30, 2013 | 42,735.00 |
| Jun 30, 2013 | -154,033.00 |
| Jun 30, 2013 | -154,033.00 |
| Mar 31, 2013 | 311,794.00 |
| Mar 31, 2013 | 311,794.00 |